SCHEMBL2644098

SCHEMBL2644098

CCS(=O)(=O)c1ccc(Oc2cc(C(=O)O)cc3c2CC(C)(C)O3)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 3/20 0.40
ALDH1A1 P00352 6/20 0.39
GAA P10253 4/20 0.39
KDM4E B2RXH2 3/20 0.39
HPGD P15428 2/20 0.39
CASP1 P29466 2/20 0.39
HSD17B10 Q99714 2/20 0.39
GLA P06280 2/20 0.39
CASP7 P55210 1/20 0.39
RXRA P19793 2/20 0.37
DAGLA Q9Y4D2 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
FFAR4 Q5NUL3 1/20 0.36
ABHD6 Q9BV23 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
POLB P06746 3/20 0.35
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL642328 0.90 GCK (0.40) GCKALDH1A1DAGLASMN1; SMN2POLB
SCHEMBL643275 0.89 PTGS2 (0.41) GCKALDH1A1GAAKDM4EHPGD
SCHEMBL2643958 0.86 ALDH1A1 (0.43) GCKALDH1A1GAAKDM4EHPGD
SCHEMBL2644255 0.85 GCK (0.39) GCKALDH1A1GAAKDM4EHPGD
SCHEMBL2645030 0.85 GCK (0.47) GCKALDH1A1GAAKDM4EHPGD
SCHEMBL2645247 0.84 GCK (0.44) GCKALDH1A1KDM4ESMN1; SMN2POLB
SCHEMBL2643952 0.84 GCK (0.39) GCKALDH1A1GAAKDM4EHPGD
SCHEMBL644806 0.81 GCK (0.54) GCKL3MBTL1
SCHEMBL642785 0.81 ALDH1A1 (0.46) GCKALDH1A1GAAKDM4EHPGD
SCHEMBL2644143 0.81 MAOB (0.43) GCKALDH1A1GAAKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
EP-2463283-A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases Pfizer Products Inc. (US) 2012-06-13 EP disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
EP-2010520-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES Pfizer Products Incorporated (US) 2009-01-07 EP disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
WO-2007122482-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PRODUCTS INC. (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 GCK 1/4885ALDH1A1 1370/4885GAA 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.